SCHEMBL4156375

SCHEMBL4156375

CN(c1ccc(F)cc1)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]cc(CCC(=O)O)c3c2c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.54
HPGD P15428 2/20 0.54
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
MAPT P10636 5/20 0.38
LMNA P02545 3/20 0.38
USP2 O75604 2/20 0.38
MEN1 O00255 2/20 0.38
ADRB2 P07550 1/20 0.38
RECQL P46063 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166925 0.92 USP2 (0.45) HSD17B10HPGDKMT2AKDM4EMAPT
SCHEMBL4162942 0.87 KDM4E (0.44) HPGDKMT2AKDM4EMAPTMEN1
SCHEMBL4162711 0.86 PTGDR2 (0.38) HSD17B10HPGDKMT2AKDM4EPTGDR2
SCHEMBL4170111 0.85 HPGD (0.42) HSD17B10HPGDKMT2AKDM4EMAPT
SCHEMBL3245348 0.84 HSD17B10 (0.69) HSD17B10HPGDKMT2AKDM4EMAPT
SCHEMBL4161163 0.84 HSD17B10 (0.50) HSD17B10HPGDKMT2AKDM4EPTGDR2
Hydrochloric Acid SCHEMBL4157674 0.83 HSD17B10 (0.49) HSD17B10HPGDKMT2AKDM4EPTGDR2
SCHEMBL4161639 0.83 HSD17B10 (0.52) HSD17B10HPGDKMT2AKDM4EPTGDR2
SCHEMBL4157963 0.82 HPGD (0.38) HSD17B10HPGDKDM4EPTGDR2HTT
SCHEMBL4161137 0.82 POLB (0.50) KMT2AMAPTMEN1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HSD17B10 3847/4885HPGD 882/4885KMT2A 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.